Whitehawk Therapeutics Inc. Ordinary Shares WHWK 深 滬
等待開盤 10-20 09:30:00 美东时间
2.21
-0.400
-15.33%
華盛通- 最 高2.57
- 今 開2.505
- 成交量 273.58万股
- 最 低 2.08
- 昨 收 2.61
- 總市值 1.04亿
- 52周最高 3.812
- 市盈率 靜 --
- 換手率 5.81%
- 52周最低 1.39
- 委 比 -76.49%
- 總股本 4712.84万
- 歷史最高 65.25
- 量 比 0.14
- 振 幅 18.77%
- 歷史最低 1.21
- 每 手 1
- 風險率 0.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | PRAX暴涨逾180%！在原发性震颤治疗领域取得重大突破；生物技术股WHWK涨超24%
PRAX暴涨逾180%！在原发性震颤治疗领域取得重大突破；WHWK涨超24%，与Tempus AI建立战略伙伴关系，共同推进肿瘤研究领域发展>>
10-17 17:43
Tempus AI Enters A Multi-Year Collaboration With Whitehawk Therapeutics To Leverage Tempus' Real-World Data And AI Capabilities For Biomarker-Driven Cancer Research
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology
10-16 20:32
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
MORRISTOWN, N.J., Sept. 2, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to e...
09-02 20:00
Whitehawk Therapeutics Q2 EPS $(0.76) Misses $0.49 Estimate
Whitehawk Therapeutics (NASDAQ:WHWK) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $0.49 by 254.16 percent. This is a 40.74 percent decrease over losses of $(0.54) per
08-07 20:11
Whitehawk Therapeutics to Participate in H.C. Wainwright "HCW@Home" Series
MORRISTOWN, N.J., June 19, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to e...
06-19 20:00
Whitehawk Therapeutics Q1 EPS $1.83 Beats $(0.46) Estimate, Sales $7.14M Up From $5.35M YoY
Whitehawk Therapeutics (NASDAQ:WHWK) reported quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $(0.46) by 497.83 percent. This is a 369.12 percent increase over losses of $(0.68) per
05-09 04:47
Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals
MORRISTOWN, N.J., March 26, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to ...
03-26 20:00
Aadi Bioscience, Now Whitehawk Therapeutics Reports Q4 2024 GAAP EPS $(0.67) Misses $(0.35) Estimate, Sales $7.239M Up From $6.326M YoY
Aadi Bioscience (NASDAQ:AADI) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.35) by 91.43 percent. This is a 11.67 percent decrease over losses of $(0.60) per share from
03-19 20:55
